Central VF progression faster in NTG with autonomic dysfunction

Article

Central visual field (VF) progression is faster in patients with normal tension glaucoma (NTG) and lower heart-rate variability than it is in NTG patients with higher heart-rate variability, according to recently published research.

Central visual field (VF) progression is faster in patients with normal tension glaucoma (NTG) and lower heart-rate variability than it is in NTG patients with higher heart-rate variability, according to research published online before print in Investigative Ophthalmology and Visual Science.

Lower heart-rate variability indicates autonomic dysfunction with sympathetic predominance, note the researchers, who add that intraocular pressure-independent risk factors such as migraine, orthostatic hypotension and autonomic dysfunction are related to central VF progression.

The Seoul, South Korea, investigators retrospectively studied 48 eyes with NTG in more than 7 VF tests during at least 5 years of follow-up. Rheumatology assessments determined their heart-rate variability.

The scientists organized patients into heart-rate-variability groups based on the standard deviation value of the qualified normal-to-normal intervals of the assessment. They divided VF into central and peripheral regions as well as superior and inferior regions. Using a linear mixed model, they examined each group’s rates of change in the mean thresholds of each designated region. They also examined potential clinical factors associated with central VF progression.

The lowest and highest heart-rate-variability groups showed similar stages of glaucoma damage, as revealed by baseline VF. The two groups also had similar mean global rate of VF changes, with only the rate of VF change in the central and superior central regions differing significantly. Significantly associated with central VF progression were baseline VF pattern standard deviation, migraine, orthostatic hypotension, and lower heart-rate-variability.

To view the abstract of the study, visit the journal's website.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.